Cargando…
Pharmacotherapies for COPD
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (L...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653890/ https://www.ncbi.nlm.nih.gov/pubmed/23700381 http://dx.doi.org/10.4137/CCRPM.S7211 |
_version_ | 1782269469394993152 |
---|---|
author | Ejiofor, Stan Turner, Alice M |
author_facet | Ejiofor, Stan Turner, Alice M |
author_sort | Ejiofor, Stan |
collection | PubMed |
description | This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines. |
format | Online Article Text |
id | pubmed-3653890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-36538902013-05-22 Pharmacotherapies for COPD Ejiofor, Stan Turner, Alice M Clin Med Insights Circ Respir Pulm Med Expert Review This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines. Libertas Academica 2013-04-25 /pmc/articles/PMC3653890/ /pubmed/23700381 http://dx.doi.org/10.4137/CCRPM.S7211 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license. |
spellingShingle | Expert Review Ejiofor, Stan Turner, Alice M Pharmacotherapies for COPD |
title | Pharmacotherapies for COPD |
title_full | Pharmacotherapies for COPD |
title_fullStr | Pharmacotherapies for COPD |
title_full_unstemmed | Pharmacotherapies for COPD |
title_short | Pharmacotherapies for COPD |
title_sort | pharmacotherapies for copd |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653890/ https://www.ncbi.nlm.nih.gov/pubmed/23700381 http://dx.doi.org/10.4137/CCRPM.S7211 |
work_keys_str_mv | AT ejioforstan pharmacotherapiesforcopd AT turneralicem pharmacotherapiesforcopd |